Oncodesign Precision Medicine S.A.

As of December 31, 2025, Oncodesign Precision Medicine S.A. carries a market capitalization of 7.47M, placing it among publicly traded companies globally. Its enterprise value stands at 11.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oncodesign Precision Medicine S.A.'s next confirmed earnings release is scheduled for April 7, 2027.

As of December 31, 2025, Oncodesign Precision Medicine S.A. has 18.12M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Oncodesign Precision Medicine S.A. maintains a current ratio of 4.76, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Oncodesign Precision Medicine S.A.'s stock has declined approximately 28.75% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.41.

As of December 31, 2025, Oncodesign Precision Medicine S.A. holds 2.11M in cash and equivalents against 6.36M in total debt, resulting in a net debt position of 6.05M. Total book value stands at 52.88M, with working capital of 10.49M providing operational flexibility.